VIP (Vasoactive Intestinal Peptide)
Peptide ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
VIP is an endogenous 28-amino-acid neuropeptide with vasodilatory, bronchodilatory, secretory, and immunomodulatory effects through VPAC receptors. Intranasal, inhaled, or injectable wellness use is not FDA-approved, although related aviptadil formulations have been studied for pulmonary and inflammatory disorders. Evidence for CIRS or general immune-repair protocols is limited and off-label.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
VIP (Vasoactive Intestinal Peptide) is a peptide most often used for studied for pulmonary immune modulation, potent vasodilatory signaling, mucosal and neuroimmune research interest. NutriStack rates the overall evidence as insufficient. A typical adult dose is No FDA-approved human dose for wellness or CIRS; inhaled research protocols are study-specific, commonly taken as investigational inhaled or intranasal product only under medical supervision. This profile indexes 3 sources.
- Flushing
- Low blood pressure
- Tachycardia or palpitations
- Hypotension or syncope tendency
- Unstable heart rhythm or severe cardiovascular disease without specialist care
The bottom line
Evidence rating insufficient. Most-documented uses: studied for pulmonary immune modulation, potent vasodilatory signaling, mucosal and neuroimmune research interest. 3 sources indexed (1991–2010), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
VIP activates VPAC1 and VPAC2 G-protein-coupled receptors, increasing cAMP signaling in immune, epithelial, smooth-muscle, and nervous-system tissues. This can relax vascular and airway smooth muscle, influence mucosal secretion, and shift inflammatory cytokine patterns. These effects also explain risks such as flushing, hypotension, tachycardia, headache, and diarrhea.
Dosing & protocol.
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Investigational Inhaled VIP.
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Full safety detail.
Side effects
- Flushing
- Low blood pressure
- Tachycardia or palpitations
- Headache
- Nasal irritation
- Diarrhea
- Dizziness
Contraindications
- Hypotension or syncope tendency
- Unstable heart rhythm or severe cardiovascular disease without specialist care
- Pregnancy and breastfeeding
- Active severe asthma, infection, or respiratory distress without medical care3
- Use of nonsterile compounded or research-grade products
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
2- 1Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosisPrasse A et al. · American Journal of Respiratory and Critical Care Medicine · 2010
Inhaled VIP altered immune readouts
- 2Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertensionPetkov V et al. · Journal of Clinical Investigation · 2003
Pulmonary hemodynamic effects were observed
Reviews & position papers
1- 3Vasoactive intestinal peptide in the lungSaid SI · Annals of the New York Academy of Sciences · 1991
VIP is active in lung tissues
Common questions.
Quick answers about VIP (Vasoactive Intestinal Peptide), drawn from the data on this page.
What is VIP (Vasoactive Intestinal Peptide)?
VIP is an endogenous 28-amino-acid neuropeptide with vasodilatory, bronchodilatory, secretory, and immunomodulatory effects through VPAC receptors. Intranasal, inhaled, or injectable wellness use is not FDA-approved, although related aviptadil formulations have been studied for pulmonary and inflammatory disorders. Evidence for CIRS or general immune-repair protocols is limited and off-label.
What is VIP (Vasoactive Intestinal Peptide) used for?
Commonly cited benefits of VIP (Vasoactive Intestinal Peptide) include: Studied for pulmonary immune modulation; Potent vasodilatory signaling; Mucosal and neuroimmune research interest; No FDA-approved wellness or CIRS indication. NutriStack rates the overall evidence as insufficient.
What is a typical dose of VIP (Vasoactive Intestinal Peptide)?
A typical adult dose of VIP (Vasoactive Intestinal Peptide) is No FDA-approved human dose for wellness or CIRS; inhaled research protocols are study-specific. The commonly recommended form is Investigational inhaled or intranasal product only under medical supervision. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of VIP (Vasoactive Intestinal Peptide)?
Reported side effects include flushing, low blood pressure, tachycardia or palpitations, headache, nasal irritation, diarrhea. This is educational information; check with a healthcare professional before use.
How strong is the evidence for VIP (Vasoactive Intestinal Peptide)?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
VIP (Vasoactive Intestinal Peptide) in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.